Schafer Boeder, MD
Endocrinology, Diabetes & Metabolism · San Diego, CANPI 1477808285
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 64.7% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $33,435, more than ten times the $250 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $1753.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$39K
- Novo Nordisk$12K
- Sanofi-aventis U.S. LLC$5K
- Lexicon Pharmaceuticals, Inc.$3K
- AstraZeneca$632
- Dexcom, Inc.$318
- plus $74 from 2 others
Across 23 payments — averaging $12,933 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$191K
- Dexcom, Inc.$86K
- Vanda Pharmaceuticals Inc.$21K
What the payments were for
- Consulting fees$30,49051%
- Speaking & faculty fees$4,2507%
- Travel & lodging$22,09237%
- Food & beverage$2,7465%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 11 | $38,539 |
| Novo Nordisk | 6 | $12,097 |
| Sanofi-aventis U.S. LLC | 4 | $4,529 |
| Lexicon Pharmaceuticals, Inc. | 2 | $3,413 |
| AstraZeneca | 7 | $632 |
| Dexcom, Inc. | 2 | $318 |
| Xeris Pharmaceuticals, Inc. | 1 | $50 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$12,097
- SOLIQUA 100/33$4,383
- Inpefa$3,413
- DEXCOM G6 TRANSMITTER$318
- DISEASE STATE$125
- FARXIGA$125
How this compares
$59,602 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in San Diego
- Juan FriasSan Diego$1.4M
- Ken FujiokaSan Diego$747K
- Raymond PlodkowskiSan Diego$546K
- Jeremy PettusSan Diego$493K
- Samantha HarrisSan Diego$113K
- Suvesh ChandiokSan Diego$71K
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.